Literature DB >> 14505222

Successful treatment with leukocytapheresis in refractory Henoch-Schönlein purpura: case report.

Tohru Nakahata1, Hiroshi Tanaka, Koichi Suzuki, Etsuro Ito.   

Abstract

A Japanese boy aged 7 years referred to our hospital because of steroid-resistant colicky abdominal pain and purpuric rash due to Henoch-Schönlein purpura (HSP). Since 2 weeks ago, he had been suffering from generalized purpuric rash and colicky abdominal pain associated with bloody diarrhea. The diagnosis was HSP. Although he had been treated with oral prednisolone and repeated intravenous coagulation factor XIII administration, the purpuric rash and colicky abdominal pain persisted. Because of steroid-resistant and refractory clinical pictures, leukocytapheresis (LCAP) using a granulocyte removal column was initiated thereafter. Following 3 times of treatment, his clinical symptoms completely disappeared and the increased levels of serum interleukin-6 were decreased to within the normal ranges. No adverse reaction was observed. These clinical observations suggested that LCAP might be beneficial to a proportion of patients with severe HSP. This is the first report to describe efficacy of LCAP in severe HSP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14505222     DOI: 10.1007/s10067-002-0695-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  4 in total

1.  Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy.

Authors:  Eishin Oki; Koji Tsugawa; Koichi Suzuki; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2008-03-12       Impact factor: 2.631

2.  Leukocytapheresis for the treatment of refractory Henoch-Schönlein purpura resistant to both prednisolone and intravenous immunoglobulin therapy.

Authors:  Eishin Oki; Koji Tsugawa; Koichi Suzuki; Etsuro Ito; Hiroshi Tanaka
Journal:  Rheumatol Int       Date:  2008-05-29       Impact factor: 2.631

3.  Leukocytapheresis for the treatment of refractory systemic-onset juvenile idiopathic arthritis.

Authors:  Hiroshi Tanaka; Koji Tsugawa; Tohru Nakahata; Koichi Suzuki; Etsuro Ito
Journal:  Clin Rheumatol       Date:  2006-03-25       Impact factor: 2.980

Review 4.  Henoch-Schönlein purpura.

Authors:  Abraham Gedalia
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.